CAR T-Cell Therapy Transforming Science and Cancer Patient Outcomes at CU Anschutz
Update: 2022-08-15
Description
This episode of CU Anschutz 360 focuses on a promising breakthrough therapy for patients with large B-cell lymphoma, an aggressive subtype of the disease. The clinical trial was led by Manali Kamdar, MD, clinical director of the lymphoma program in the Division of Hematology at the University of Colorado School of Medicine. In the trial for relapsed patients or patients who didn’t respond to treatment initially, CAR T-cell therapy with lisocabtagene maraleucel showed significant improvement in keeping patients in remission when compared to the standard-of-care, which consisted of chemotherapy followed by stem cell transplantation. Thomas Flaig, MD, vice chancellor for research, co-hosts the discussion.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
